S

Sanofi

Global pharma company; vaccines and R&D

GRA Labelling Group Lead

Full-TimeDeadline 10/31/26
No salary listed
Expert
Bachelor's, Master's
Hyderabad, Telangana, India
HybridHybrid work in Hyderabad.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Knowledge of regulatory and labeling requirements in major markets for marketing authorization filings for new products or updates to marketed products.
  • Extensive knowledge of drug labeling requirements, including CCDS, European Union and United States guidance and regulations, and drug-device combinations.
  • Ability to lead labeling strategy and connect it to regulatory strategy.
  • Ability to lead matrix teams, manage up, negotiate, and build consensus on complex topics.
  • Ability to lead multidisciplinary labeling working groups involving Global Regulatory Affairs, Global Pharmacovigilance, Global Medical Affairs, Legal, preclinical, and CMC functions.
  • Deep knowledge of end-to-end labeling processes and interfaces between Regulatory, Medical Affairs, Pharmacovigilance, Quality, and Supply Chain.
  • At least 15 years of relevant regulatory and labeling experience.
  • At least 5 years of people management, team management, and project management experience.
  • Ability to recruit, hire, and onboard staff, including defining role competencies and evaluating candidates.
  • Experience building and executing training plans, assessing competency, and closing individual training gaps through targeted development.
  • Experience conducting performance management through goal setting, feedback, and coaching for a team.
  • Ability to assign and balance product responsibility across a team based on capacity and skill level.
  • Experience managing resource planning and coverage across vacations, turnover, sick leave, and peak workloads without disrupting deliverables.
  • Ability to forecast capacity against portfolio demand and reallocate work when gaps emerge.
  • Experience developing contingency and backup coverage models so no product goes unowned.
  • Experience establishing and monitoring quality and timeliness KPIs and metrics.
  • Working knowledge of project and portfolio management methods for competing deadlines across a large product portfolio.
  • Ability to work with associates and management at all company levels, domestically and internationally.
  • Ability to support global discussions and local countries as a global labeling subject matter expert.
  • Ability to construct and guide creation of company responses to European Union and United States health authority questions related to labeling.
  • Ability to build or learn scientific knowledge, such as statistics and disease-area knowledge, to work across therapeutic areas.
  • Familiarity with labeling and document management systems, including Veeva Vault, EDMS, RIM systems, and text verification or quality-control tools.
  • Ability to search public data on labeling elements and regulatory strategy.
  • Demonstrated ability to track and report portfolio status using dashboards, trackers, or portfolio management tools.
  • Physician, Pharmacist, Veterinarian, or Life Sciences degree.
  • Fluent business English.
Responsibilities
  • Recruit, hire, and onboard team members, including defining role competencies and evaluating candidates.
  • Build and execute training plans, assess team-member competency, and close individual training gaps through targeted development.
  • Conduct performance management through goal setting, feedback, and coaching for a team.
  • Assign and balance product responsibility across a team based on capacity and skill level.
  • Manage resource planning and coverage across vacations, turnover, sick leave, and peak workloads without disrupting deliverables.
  • Ensure coverage for products and projects within the group by identifying gaps and resource constraints and implementing solutions for management consideration.
  • Forecast capacity against portfolio demand and reallocate work when gaps emerge.
  • Develop contingency and backup coverage models so no product goes unowned.
  • Track and report status across a large portfolio using dashboards, trackers, or portfolio management tools.
  • Establish and monitor KPIs and metrics for labeling quality and timeliness, including on-time submission rate, error or deviation rate, and cycle time.
  • Use project and portfolio management methods to manage competing deadlines across 250 products.
  • Lead labeling strategists in creating or updating corporate labeling documents and corresponding patient leaflets for development, lifecycle-management, and marketed products.
  • Coordinate and ensure accountability throughout the end-to-end labeling review and approval process.
  • Prepare labeling components for submission to regulatory agencies and participate in labeling negotiations that result in product approvals or updates.
  • Ensure the team supports cross-functional groups as a labeling expert and contributes to global regulatory strategies and submission dossiers or health-authority responses.
  • Chair multidisciplinary labeling working groups, present labeling proposals, and develop consensus for presentation to the Labeling Governance Committee.
  • Provide oversight and guidance for the team and assigned products, including strategic guidance and training for complex labeling projects.
  • Serve as a representative of the extended Global Regulatory Affairs Labeling Leadership team.
  • Participate in response teams for highly complex European Union and United States procedures, including arbitration, referrals, work sharing, PRAC questions, signal detection, labeling negotiations, and urgent safety restrictions.
  • Identify portfolio risks and implementation hurdles and act to minimize them while informing management as needed.
  • Coordinate, create, and clearly present labeling proposals to Senior Executive Management through the Labeling Review Committee.
  • Guide assessment of relevant study reports, post-marketing pharmacovigilance data, and other scientific reports supporting labeling proposals.
  • Direct complex labeling competitive and comparator analyses to provide expert-level insights.
  • Meet established submission timelines and quality standards for labeling deliverables.
  • Provide training and mentoring to junior labeling team members on CCDS, European Union and United States guidance and regulations, and their implementation in labeling text.
  • Lead complex transversal or process-improvement workstreams across labeling and Global Regulatory Affairs topics.
  • Interpret and apply health-authority requirements from the Food and Drug Administration, European Medicines Agency, and other relevant agencies.
Desired Qualifications
  • An advanced degree.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)